Fluphenazine Decanoate Comprehensive Study by Application (Acute Schizophrenia, Chronic Schizophrenia, Others), Sales Channel (Hospital Pharmacy, Retail Pharmacy, Other), End User (Children, Adult) Players and Region - Global Market Outlook to 2030

Fluphenazine Decanoate Market by XX Submarkets | Forecast Years 2024-2030  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Fluphenazine Decanoate Market Overview:
Fluphenazine Decanoate drug is long-acting fluphenazine that is used to treat a variety of psychiatric and mood disorders (chronic schizophrenia). Patients who have benefited from daily doses of short-acting fluphenazine and who may benefit from long-term (maintenance) therapy with less frequent dosing should consider fluphenazine decanoate. This medication is usually pale yellow in color.

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Growing R& D Activities across the Globe

Market Growth Drivers:
Increasing Number of People Who Are Suffering From Behavioral Health and Rising Cases of Schizophrenia across the Globe

Challenges:
Stringent Government Rules and Regulations

Restraints:
Side Effects such as Dizziness, Lightheadedness, Nausea

Opportunities:
Emerging Demand from both Developing and Developed Economies and Growth in the Healthcare Sector in Developing Countries

Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Atlantic Laboratories Corporation,Ltd. (Thailand), West Ward Pharmaceuticals (United States), Shanghai Zhongxi Sunve Pharmaceutical (China), Southwest Pharmaceutical (China), Shanghai Harvest Pharmaceutical (China), Par Sterile Products, LLC (United States), Aurobindo Pharma Limited (India) and Fresenius Kabi (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Fluphenazine Decanoate market by 2030. Considering Market by Sales Channel, the sub-segment i.e. Hospital Pharmacy will boost the Fluphenazine Decanoate market. Considering Market by End User, the sub-segment i.e. Children will boost the Fluphenazine Decanoate market.

Latest Market Insights:
In October 2023, Sandoz, a Novartis division, received FDA approval for its generic version of Xepin (Fluphenazine Decanoate) injectable suspension. However, a launch date has not been announced yet.

In April 2023, Sun Pharma launched Fluphenazine Decanoate Injection USP 25mg/ml in the US market. This was a new dosage form of the existing medication, offering a more convenient option for patients.

What Can be Explored with the Fluphenazine Decanoate Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Fluphenazine Decanoate Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Fluphenazine Decanoate
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Fluphenazine Decanoate market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Fluphenazine Decanoate market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Fluphenazine Decanoate Manufacturer, Raw Material Suppliers, Government Regulatory and Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Application
  • Acute Schizophrenia
  • Chronic Schizophrenia
  • Others
By Sales Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Other

By End User
  • Children
  • Adult

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of People Who Are Suffering From Behavioral Health
      • 3.2.2. Rising Cases of Schizophrenia across the Globe
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Growing R& D Activities across the Globe
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Fluphenazine Decanoate, by Application, Sales Channel, End User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Fluphenazine Decanoate (Value)
      • 5.2.1. Global Fluphenazine Decanoate by: Application (Value)
        • 5.2.1.1. Acute Schizophrenia
        • 5.2.1.2. Chronic Schizophrenia
        • 5.2.1.3. Others
      • 5.2.2. Global Fluphenazine Decanoate by: Sales Channel (Value)
        • 5.2.2.1. Hospital Pharmacy
        • 5.2.2.2. Retail Pharmacy
        • 5.2.2.3. Other
      • 5.2.3. Global Fluphenazine Decanoate by: End User (Value)
        • 5.2.3.1. Children
        • 5.2.3.2. Adult
      • 5.2.4. Global Fluphenazine Decanoate Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Fluphenazine Decanoate (Price)
  • 6. Fluphenazine Decanoate: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Atlantic Laboratories Corporation,Ltd. (Thailand)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. West Ward Pharmaceuticals (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Shanghai Zhongxi Sunve Pharmaceutical (China)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Southwest Pharmaceutical (China)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Shanghai Harvest Pharmaceutical (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Par Sterile Products, LLC (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Aurobindo Pharma Limited (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Fresenius Kabi (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Fluphenazine Decanoate Sale, by Application, Sales Channel, End User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Fluphenazine Decanoate (Value)
      • 7.2.1. Global Fluphenazine Decanoate by: Application (Value)
        • 7.2.1.1. Acute Schizophrenia
        • 7.2.1.2. Chronic Schizophrenia
        • 7.2.1.3. Others
      • 7.2.2. Global Fluphenazine Decanoate by: Sales Channel (Value)
        • 7.2.2.1. Hospital Pharmacy
        • 7.2.2.2. Retail Pharmacy
        • 7.2.2.3. Other
      • 7.2.3. Global Fluphenazine Decanoate by: End User (Value)
        • 7.2.3.1. Children
        • 7.2.3.2. Adult
      • 7.2.4. Global Fluphenazine Decanoate Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Fluphenazine Decanoate (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Fluphenazine Decanoate: by Application(USD Million)
  • Table 2. Fluphenazine Decanoate Acute Schizophrenia , by Region USD Million (2018-2023)
  • Table 3. Fluphenazine Decanoate Chronic Schizophrenia , by Region USD Million (2018-2023)
  • Table 4. Fluphenazine Decanoate Others , by Region USD Million (2018-2023)
  • Table 5. Fluphenazine Decanoate: by Sales Channel(USD Million)
  • Table 6. Fluphenazine Decanoate Hospital Pharmacy , by Region USD Million (2018-2023)
  • Table 7. Fluphenazine Decanoate Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 8. Fluphenazine Decanoate Other , by Region USD Million (2018-2023)
  • Table 9. Fluphenazine Decanoate: by End User(USD Million)
  • Table 10. Fluphenazine Decanoate Children , by Region USD Million (2018-2023)
  • Table 11. Fluphenazine Decanoate Adult , by Region USD Million (2018-2023)
  • Table 12. South America Fluphenazine Decanoate, by Country USD Million (2018-2023)
  • Table 13. South America Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 14. South America Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 15. South America Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 16. Brazil Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 17. Brazil Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 18. Brazil Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 19. Argentina Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 20. Argentina Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 21. Argentina Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 22. Rest of South America Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 23. Rest of South America Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 24. Rest of South America Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 25. Asia Pacific Fluphenazine Decanoate, by Country USD Million (2018-2023)
  • Table 26. Asia Pacific Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 27. Asia Pacific Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 28. Asia Pacific Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 29. China Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 30. China Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 31. China Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 32. Japan Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 33. Japan Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 34. Japan Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 35. India Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 36. India Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 37. India Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 38. South Korea Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 39. South Korea Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 40. South Korea Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 41. Taiwan Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 42. Taiwan Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 43. Taiwan Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 44. Australia Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 45. Australia Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 46. Australia Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 50. Europe Fluphenazine Decanoate, by Country USD Million (2018-2023)
  • Table 51. Europe Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 52. Europe Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 53. Europe Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 54. Germany Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 55. Germany Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 56. Germany Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 57. France Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 58. France Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 59. France Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 60. Italy Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 61. Italy Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 62. Italy Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 63. United Kingdom Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 64. United Kingdom Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 65. United Kingdom Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 66. Netherlands Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 67. Netherlands Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 68. Netherlands Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 69. Rest of Europe Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 70. Rest of Europe Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 71. Rest of Europe Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 72. MEA Fluphenazine Decanoate, by Country USD Million (2018-2023)
  • Table 73. MEA Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 74. MEA Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 75. MEA Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 76. Middle East Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 77. Middle East Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 78. Middle East Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 79. Africa Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 80. Africa Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 81. Africa Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 82. North America Fluphenazine Decanoate, by Country USD Million (2018-2023)
  • Table 83. North America Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 84. North America Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 85. North America Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 86. United States Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 87. United States Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 88. United States Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 89. Canada Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 90. Canada Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 91. Canada Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 92. Mexico Fluphenazine Decanoate, by Application USD Million (2018-2023)
  • Table 93. Mexico Fluphenazine Decanoate, by Sales Channel USD Million (2018-2023)
  • Table 94. Mexico Fluphenazine Decanoate, by End User USD Million (2018-2023)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Fluphenazine Decanoate: by Application(USD Million)
  • Table 104. Fluphenazine Decanoate Acute Schizophrenia , by Region USD Million (2025-2030)
  • Table 105. Fluphenazine Decanoate Chronic Schizophrenia , by Region USD Million (2025-2030)
  • Table 106. Fluphenazine Decanoate Others , by Region USD Million (2025-2030)
  • Table 107. Fluphenazine Decanoate: by Sales Channel(USD Million)
  • Table 108. Fluphenazine Decanoate Hospital Pharmacy , by Region USD Million (2025-2030)
  • Table 109. Fluphenazine Decanoate Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 110. Fluphenazine Decanoate Other , by Region USD Million (2025-2030)
  • Table 111. Fluphenazine Decanoate: by End User(USD Million)
  • Table 112. Fluphenazine Decanoate Children , by Region USD Million (2025-2030)
  • Table 113. Fluphenazine Decanoate Adult , by Region USD Million (2025-2030)
  • Table 114. South America Fluphenazine Decanoate, by Country USD Million (2025-2030)
  • Table 115. South America Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 116. South America Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 117. South America Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 118. Brazil Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 119. Brazil Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 120. Brazil Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 121. Argentina Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 122. Argentina Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 123. Argentina Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 124. Rest of South America Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 125. Rest of South America Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 126. Rest of South America Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 127. Asia Pacific Fluphenazine Decanoate, by Country USD Million (2025-2030)
  • Table 128. Asia Pacific Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 129. Asia Pacific Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 130. Asia Pacific Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 131. China Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 132. China Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 133. China Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 134. Japan Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 135. Japan Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 136. Japan Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 137. India Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 138. India Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 139. India Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 140. South Korea Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 141. South Korea Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 142. South Korea Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 143. Taiwan Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 144. Taiwan Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 145. Taiwan Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 146. Australia Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 147. Australia Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 148. Australia Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 149. Rest of Asia-Pacific Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 150. Rest of Asia-Pacific Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 151. Rest of Asia-Pacific Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 152. Europe Fluphenazine Decanoate, by Country USD Million (2025-2030)
  • Table 153. Europe Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 154. Europe Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 155. Europe Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 156. Germany Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 157. Germany Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 158. Germany Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 159. France Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 160. France Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 161. France Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 162. Italy Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 163. Italy Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 164. Italy Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 165. United Kingdom Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 166. United Kingdom Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 167. United Kingdom Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 168. Netherlands Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 169. Netherlands Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 170. Netherlands Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 171. Rest of Europe Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 172. Rest of Europe Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 173. Rest of Europe Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 174. MEA Fluphenazine Decanoate, by Country USD Million (2025-2030)
  • Table 175. MEA Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 176. MEA Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 177. MEA Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 178. Middle East Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 179. Middle East Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 180. Middle East Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 181. Africa Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 182. Africa Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 183. Africa Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 184. North America Fluphenazine Decanoate, by Country USD Million (2025-2030)
  • Table 185. North America Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 186. North America Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 187. North America Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 188. United States Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 189. United States Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 190. United States Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 191. Canada Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 192. Canada Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 193. Canada Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 194. Mexico Fluphenazine Decanoate, by Application USD Million (2025-2030)
  • Table 195. Mexico Fluphenazine Decanoate, by Sales Channel USD Million (2025-2030)
  • Table 196. Mexico Fluphenazine Decanoate, by End User USD Million (2025-2030)
  • Table 197. Research Programs/Design for This Report
  • Table 198. Key Data Information from Secondary Sources
  • Table 199. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Fluphenazine Decanoate: by Application USD Million (2018-2023)
  • Figure 5. Global Fluphenazine Decanoate: by Sales Channel USD Million (2018-2023)
  • Figure 6. Global Fluphenazine Decanoate: by End User USD Million (2018-2023)
  • Figure 7. South America Fluphenazine Decanoate Share (%), by Country
  • Figure 8. Asia Pacific Fluphenazine Decanoate Share (%), by Country
  • Figure 9. Europe Fluphenazine Decanoate Share (%), by Country
  • Figure 10. MEA Fluphenazine Decanoate Share (%), by Country
  • Figure 11. North America Fluphenazine Decanoate Share (%), by Country
  • Figure 12. Global Fluphenazine Decanoate share by Players 2023 (%)
  • Figure 13. Global Fluphenazine Decanoate share by Players (Top 3) 2023(%)
  • Figure 14. Global Fluphenazine Decanoate share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Atlantic Laboratories Corporation,Ltd. (Thailand) Revenue, Net Income and Gross profit
  • Figure 17. Atlantic Laboratories Corporation,Ltd. (Thailand) Revenue: by Geography 2023
  • Figure 18. West Ward Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 19. West Ward Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 20. Shanghai Zhongxi Sunve Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 21. Shanghai Zhongxi Sunve Pharmaceutical (China) Revenue: by Geography 2023
  • Figure 22. Southwest Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 23. Southwest Pharmaceutical (China) Revenue: by Geography 2023
  • Figure 24. Shanghai Harvest Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 25. Shanghai Harvest Pharmaceutical (China) Revenue: by Geography 2023
  • Figure 26. Par Sterile Products, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 27. Par Sterile Products, LLC (United States) Revenue: by Geography 2023
  • Figure 28. Aurobindo Pharma Limited (India) Revenue, Net Income and Gross profit
  • Figure 29. Aurobindo Pharma Limited (India) Revenue: by Geography 2023
  • Figure 30. Fresenius Kabi (United States) Revenue, Net Income and Gross profit
  • Figure 31. Fresenius Kabi (United States) Revenue: by Geography 2023
  • Figure 32. Global Fluphenazine Decanoate: by Application USD Million (2025-2030)
  • Figure 33. Global Fluphenazine Decanoate: by Sales Channel USD Million (2025-2030)
  • Figure 34. Global Fluphenazine Decanoate: by End User USD Million (2025-2030)
  • Figure 35. South America Fluphenazine Decanoate Share (%), by Country
  • Figure 36. Asia Pacific Fluphenazine Decanoate Share (%), by Country
  • Figure 37. Europe Fluphenazine Decanoate Share (%), by Country
  • Figure 38. MEA Fluphenazine Decanoate Share (%), by Country
  • Figure 39. North America Fluphenazine Decanoate Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Atlantic Laboratories Corporation,Ltd. (Thailand)
  • West Ward Pharmaceuticals (United States)
  • Shanghai Zhongxi Sunve Pharmaceutical (China)
  • Southwest Pharmaceutical (China)
  • Shanghai Harvest Pharmaceutical (China)
  • Par Sterile Products, LLC (United States)
  • Aurobindo Pharma Limited (India)
  • Fresenius Kabi (United States)
Select User Access Type

Key Highlights of Report


Feb 2024 208 Pages 89 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Fluphenazine Decanoate market are Atlantic Laboratories Corporation,Ltd. (Thailand), West Ward Pharmaceuticals (United States), Shanghai Zhongxi Sunve Pharmaceutical (China), Southwest Pharmaceutical (China), Shanghai Harvest Pharmaceutical (China), Par Sterile Products, LLC (United States), Aurobindo Pharma Limited (India) and Fresenius Kabi (United States), to name a few.
"Growing R& D Activities across the Globe" is seen as one of major influencing trends for Fluphenazine Decanoate Market during projected period 2023-2030.

Know More About Global Fluphenazine Decanoate Market Report?